Therapie · 2026
[Systematic review of the literature and evaluation of the effectiveness of muscle relaxants in acute low back pain according to REB method].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Langelier Hélène, Pires Julio, Boussageon Rémy
Аннотация
INTRODUCTION: Acute low back pain (LBP), with or without radiculopathy, is a common condition in primary care. In practice, muscle relaxants are widely used, although their effectiveness remains controversial. A 2021 meta-analysis of randomized controlled trials (RCTs) suggested possible efficacy but with a low level of evidence.
OBJECTIVES: The aim of this study is to evaluate the effectiveness of three muscle relaxants (thiocolchicoside, methocarbamol, and diazepam) commonly used in practice for improving pain and functionality in acute low back pain with or without radiculopathy through a systematic review of RCTs, with assessment of the level of evidence according to the REB (Rebuild the Evidence Base) method.
METHODS: A systematic search was conducted in three databases (Medline, Cochrane, and Embase) and the ClinicalTrials.gov registry up to March 31, 2024. The risk of bias was assessed using the RoB2 tool. The primary outcomes were pain improvement and functional recovery. The REB method was applied to evaluate the global level of evidence for the effectiveness of each molecule. PROSPERO Protocol: CRD42024564738.
RESULTS: Eight trials were included: thiocolchicoside (4 RCTs, 604 patients), methocarbamol (2 RCTs, 223 patients), diazepam (2 RCTs, 164 patients). The RCTs evaluating the effectiveness of thiocolchicoside were all at high risk of bias. For methocarbamol, one RCT had a low risk of bias and showed a functional improvement of 2.8 points in favor of the placebo (95% CI: 0.0 to 5.7), which was not statistically significant. For diazepam, one RCT with a low risk of bias reported a functional improvement of +0.3 points in favor of the placebo (95% CI: -2.8 to 3.5), which was also not statistically significant.
CONCLUSION: According to the REB method, none of the three molecules demonstrated efficacy in acute low back pain with or without radiculopathy.
OBJECTIVES: The aim of this study is to evaluate the effectiveness of three muscle relaxants (thiocolchicoside, methocarbamol, and diazepam) commonly used in practice for improving pain and functionality in acute low back pain with or without radiculopathy through a systematic review of RCTs, with assessment of the level of evidence according to the REB (Rebuild the Evidence Base) method.
METHODS: A systematic search was conducted in three databases (Medline, Cochrane, and Embase) and the ClinicalTrials.gov registry up to March 31, 2024. The risk of bias was assessed using the RoB2 tool. The primary outcomes were pain improvement and functional recovery. The REB method was applied to evaluate the global level of evidence for the effectiveness of each molecule. PROSPERO Protocol: CRD42024564738.
RESULTS: Eight trials were included: thiocolchicoside (4 RCTs, 604 patients), methocarbamol (2 RCTs, 223 patients), diazepam (2 RCTs, 164 patients). The RCTs evaluating the effectiveness of thiocolchicoside were all at high risk of bias. For methocarbamol, one RCT had a low risk of bias and showed a functional improvement of 2.8 points in favor of the placebo (95% CI: 0.0 to 5.7), which was not statistically significant. For diazepam, one RCT with a low risk of bias reported a functional improvement of +0.3 points in favor of the placebo (95% CI: -2.8 to 3.5), which was also not statistically significant.
CONCLUSION: According to the REB method, none of the three molecules demonstrated efficacy in acute low back pain with or without radiculopathy.